Core Viewpoint - The NewCo model is increasingly becoming a preferred strategy for Chinese pharmaceutical companies to expand internationally, with significant financial implications and advantages over traditional business development (BD) models [1][3]. Group 1: NewCo Model Overview - NewCo refers to the establishment of a new company that holds overseas rights to a pharmaceutical product, allowing for international management and potential exit through IPO or acquisition [3]. - Compared to traditional BD models, NewCo offers advantages in collaboration structure, ownership distribution, financial flexibility, and market entry [3]. - Traditional BD models face high uncertainty after transferring pipeline rights, while NewCo allows for shared decision-making and risk management [3][4]. Group 2: Advantages of NewCo Model - The NewCo model optimizes the asset and funding matching process for innovative drugs, enabling early-stage pipelines to secure funding from U.S. venture capital without affecting domestic listings [4]. - It accelerates research and international registration processes, allowing products to enter overseas markets more quickly while reducing financial pressure on pharmaceutical companies [5]. - NewCo provides stronger control and protection for Chinese companies, allowing them to retain equity and benefit from long-term value appreciation through various revenue streams [5]. Group 3: Market Outlook and Opportunities - The NewCo model is seen as a vital pathway for Chinese pharmaceutical companies to achieve internationalization, leveraging advantages such as population demand, manufacturing capabilities, and growing innovation [8]. - The industry is expected to continue seeing growth opportunities in innovation, international expansion, and market consolidation as the NewCo trend evolves [8].

Core Viewpoint - Heng Rui Medicine has entered into an agreement with GSK, involving an upfront payment of $500 million and potential milestone payments of up to $12 billion, leading to a significant surge in its stock price [2][4]. Financial Terms - GSK will pay Heng Rui an upfront fee of $500 million, with potential total milestone payments reaching approximately $12 billion if all projects are exercised and milestones achieved [7]. - Heng Rui will also be entitled to receive a tiered sales commission from GSK, excluding regions in mainland China and Hong Kong, Macau, and Taiwan [7]. Project Details - The HRS-9821 project is a potential best-in-class PDE3/4 inhibitor currently in clinical development for chronic obstructive pulmonary disease (COPD) [4]. - The agreement includes exclusive licensing rights for up to 11 additional projects in various therapeutic areas, including oncology, respiratory, autoimmune, and inflammatory diseases, which are currently in non-clinical research stages [4][5]. Strategic Implications - The agreement is expected to broaden the overseas market for HRS-9821 and other innovative products, enhancing the company's brand and overseas performance [8]. - Since 2018, Heng Rui has engaged in 13 licensing transactions with global partners, involving 16 molecular entities and a potential total transaction value of approximately $14 billion, with an upfront payment total of around $600 million [8]. - The company's internationalization process is anticipated to accelerate, especially with recent leadership changes and a robust pipeline of over 90 innovative products in clinical development [8].

【导读】恒瑞医药与 GSK 达成协议，首付款为 5 亿美元，里程碑付款或达 120 亿美元，股 价暴涨 中国基金报记者 卢鸰 恒瑞医药又有大动作。 恒瑞医药 7 月 28 日早间公告，与知名跨国药企 GSK 达成协议，将 HRS-9821 项目的全球 独家权利和至多 11 个项目的全球独家许可的独家选择权有偿许可给 GSK， 首付款为 5 亿 美元，里程碑付款或达 120 亿美元。 里程碑付款或达 120 亿美元 HRS-9821 是一款潜在的同类最佳 PDE3/4 抑制剂，目前正处于临床开发阶段，可用于治疗 慢性阻塞性肺病（ COPD ）。其他 11 个项目涉及肿瘤、呼吸、自免和炎症等多个治疗领域 的创新药物，目前均处于非临床研究阶段。 根据协议，恒瑞将主导这些项目的研发，最晚至完成包括海外受试者数据的 Ⅰ 期临床试验。 GSK 将拥有在最晚至 Ⅰ 期临床完成时，行使全球（不包括中国大陆、港澳台）进一步开发 和商业化每个项目的独家选择权，以及某些项目替换权。 财务条款方面， GSK 将向恒瑞支付 5 亿美元的首付款；如果所有项目均获得行使选择权且 所有里程碑均已实现，恒瑞将有资格获得未来基于成功开发、注册和 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Views - The innovation environment is continuously improving, leading to an optimistic outlook on innovation premiums. In the first half of 2025, global pharmaceutical transactions reached 456, a 32% year-on-year increase, with total upfront payments soaring to $11.8 billion, a 136% increase. The total transaction value hit $130.4 billion, up 58% year-on-year, with Chinese companies contributing nearly 50% of the total value and over 30% of the transaction count [3] - The CXO sector is expected to gradually recover following a supply-side cleansing post-COVID-19, with a significant increase in License-out transactions and total transaction amounts surpassing previous years [4] - The TCE technology is being continuously iterated and updated, with promising clinical data emerging for TCE-based therapies, indicating a strong market potential [5] - The trend towards more effective and scientific weight loss solutions is evident, with GLP-1 drugs generating over $50 billion in global sales, driving capital interest in the sector [6] - There is a growing focus on autoimmune diseases, with significant clinical data supporting new treatments and collaborations in the field [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.21 percentage points in the last week, with a weekly increase of 1.90% [18] - Over the past month, the industry outperformed the CSI 300 index by 6.73 percentage points, with a monthly increase of 10.95% [21][24] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical and biotechnology industry index currently has a PE (TTM) of 37.98, above the 5-year historical average of 32.08 [41] 3. Recent Research Achievements - The report highlights various recent research findings, including the positive outlook for the blood products industry and the acceleration of the inhalation drug sector due to policy support [45] 4. Recent Industry Policies and News - The National Healthcare Security Administration has implemented measures to support the high-quality development of innovative drugs, enhancing the support for R&D and clinical applications [46] - Recent news includes significant approvals and collaborations in the pharmaceutical sector, indicating a vibrant market environment [48][49] 5. Key Company Recommendations - The report recommends specific companies based on their potential to benefit from the improving innovation environment and market trends, including CXO firms and those involved in TCE technology [8]

Core Insights - Domestic innovative drugs are experiencing a surge in overseas collaborations, with over 50 global partnership agreements reached by mid-2025, totaling more than $48.4 billion [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index has seen a year-to-date increase of 93.18% as of July 18, 2025, indicating strong investor interest in the sector [1] - Supportive measures for innovative drug development have been implemented, enhancing market accessibility and encouraging increased R&D investment from pharmaceutical companies [1] - The integration of AI technology in drug development is significantly reducing R&D cycles and costs, accelerating the internationalization of innovative drugs [1] Industry Performance - The innovative drug sector is becoming a key focus in the market, with notable performance from certain healthcare funds, such as Zhongyin Innovation Medical A and Zhongyin Hong Kong Stock Connect Medical A, which have increased by 63.64% and 84.18% respectively over the past year [2] - The total profit for the innovative drug sector is projected to grow from 60 billion yuan to 600-900 billion yuan over the next 10-15 years, highlighting its potential for future growth [2] Fund Performance - Zhongyin Hong Kong Stock Connect Medical A has shown a net value growth rate of 70.08% in the first half of 2025, outperforming its benchmark by 32.79% [3] - Zhongyin Innovation Medical A has achieved a net value growth rate of 54.08% in the first half of 2025, significantly exceeding its benchmark [4] - The performance of other funds managed by Zhongyin, such as Zhongyin Healthcare Mixed A and C, also reflects strong growth, with 51.59% and 51.31% increases respectively in the first half of 2025 [5]

Group 1 - The core viewpoint of the articles highlights the active performance of innovative drug stocks in the Hong Kong market, with the Hong Kong Innovative Drug 50 ETF (513780) rising over 87% year-to-date and experiencing significant net inflows since June [1][2] - Key individual stocks such as Kailaiying, CanSino Biologics, and others have shown substantial gains, indicating strong investor interest and confidence in the sector [1] - The National Healthcare Security Administration has initiated the 11th batch of centralized procurement, optimizing selection rules to ensure fair pricing and cost coverage for selected enterprises, which may positively impact the innovative drug market [1][2] Group 2 - Guosen Securities continues to recommend the innovative drug sector, citing improvements in both domestic and overseas markets, with recent adjustments to the medical insurance catalog providing economic support for innovative drug development [2] - The top ten constituents of the CSI Hong Kong Stock Connect Innovative Drug Index account for 69.16% of the index, including high-quality A-share companies involved in drug research and development [2] - The innovative drug sector is positioned at a new historical starting point, with domestic companies enhancing competitiveness and expanding overseas, supported by rapid revenue growth and favorable policies [2]

Group 1 - The Hang Seng Healthcare Index (HSHCI) has seen a strong increase of 1.56%, with notable gains from stocks such as MicroPort Medical (00853) up 16.53% and WuXi AppTec (02268) [3] - The Hang Seng Healthcare ETF (513060) rose by 1.24%, with a recent price of 0.65 yuan, and has accumulated a 4.21% increase over the past week [3] - The National Healthcare Security Administration reported that since the 14th Five-Year Plan, 402 types of drugs have been added to the national medical insurance drug list, which now includes a total of 3,159 drugs [3] Group 2 - CD3 T cell engagers (TCE) are gaining significant attention in the field of autoimmune diseases, with advantages such as precise targeting and reduced toxicity [4] - The Hang Seng Healthcare ETF has a current scale of 79.17 billion yuan, ranking in the top third among comparable funds [4] - The ETF has shown a net value increase of 30.43% over the past two years, with a maximum monthly return of 28.34% since its inception [4] Group 3 - The Hang Seng Healthcare ETF has a Sharpe ratio of 2.22 for the past year, indicating strong risk-adjusted returns [5] - The ETF's management fee is 0.50%, and the tracking error over the past year is 0.060%, the highest precision among comparable funds [5] - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Healthcare Index is 31.13, indicating it is at a historical low compared to the past three years [5] Group 4 - The top ten weighted stocks in the Hang Seng Healthcare Index account for 60.62% of the index, including companies like BeiGene (06160) and Innovent Biologics (01801) [6] - The ETF is closely tracking the Hang Seng Healthcare Index, which serves as a market reference for healthcare-related securities listed in Hong Kong [5][6]

Core Viewpoint - The successful FDA approval of ZEGFROVY (舒沃替尼片) marks a significant milestone for the company as it becomes the first independently developed innovative drug from China to enter the global market, with expectations of reaching over 10 billion yuan in global sales peak [1][2]. Group 1: Product Approval and Market Potential - ZEGFROVY has received accelerated approval from the FDA for treating adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations [1]. - The drug is the only approved small molecule targeted therapy for EGFR exon 20 insertion NSCLC in China, with a projected peak sales in the Chinese market of approximately 3.076 billion yuan [2]. - The approval in the U.S. opens up new market opportunities, with a potential global sales peak estimated at 12.954 billion yuan [2]. Group 2: Commercialization Strategy - The company is currently evaluating various overseas market expansion models, aiming to maximize long-term benefits and shareholder returns [3]. - The CEO indicated that the overseas market could become a significant growth driver, while the domestic market remains crucial [3]. - The company has a commercial team nearing 500 members to enhance market coverage for its products [3]. Group 3: Research and Development Pipeline - The company has a robust pipeline with seven drug candidates in international multi-center clinical stages, focusing on unmet medical needs in lung cancer and hematological malignancies [3][4]. - DZD6008, a selective EGFR TKI, shows promise in treating NSCLC patients who have failed multiple lines of therapy [5]. - DZD8586 is a novel dual-target inhibitor that addresses resistance mechanisms in B-cell non-Hodgkin lymphoma, demonstrating good anti-tumor activity [6]. Group 4: Financial Performance and Investment - The company has seen a reduction in net losses, with a reported loss of approximately 850 million yuan in 2024, down 24% year-on-year [7]. - The company successfully raised nearly 1.8 billion yuan through a private placement, with plans to invest over 1 billion yuan in new drug research and development [8]. - The company is actively assessing potential partners for business development (BD) to enhance its global strategy without compromising long-term value [9].

Core Insights - The Chinese biotech sector is experiencing a structural revaluation, with the Hong Kong innovative drug sector showing a year-to-date increase of over 60% as of June 2025, driven by significant global collaborations in innovative drugs [1] - Hengrui Medicine has become a key player in the internationalization of Chinese innovative drugs, achieving over $10 billion in overseas transactions, including a $45.75 billion deal with AstraZeneca and a $6.7 billion partnership with Otsuka Pharmaceutical [1][2] - The company has seen its stock price rise over 300% in the first half of 2025 and is one of the few Hong Kong-listed companies that have achieved profitability for two consecutive years, indicating a sustainable business model [1][2] Group 1: Industry Trends - The Chinese innovative drug sector is transitioning from a focus on the quantity of pipelines to the value of technology, with companies like BeiGene and Ilyas successfully selling products overseas, where international sales now account for over half of their revenue [2] - The industry faces challenges, including the uncertainty of future product launches and the sustainability of business development (BD) transactions, which can lead to significant revenue fluctuations [2] - The high-risk nature of innovative drug development necessitates that companies find sustainable paths to navigate the "valley of death" in the industry [2] Group 2: Hengrui Medicine's Strategy - Hengrui Medicine has been labeled the "King of BD" due to its frequent license-out transactions, which are strategically aligned with its core technology platform [2][3] - The company has established a strong global collaboration network, with over 300 projects in partnership with leading firms like AstraZeneca and Pfizer, focusing on providing comprehensive preclinical solutions [4] - Hengrui Medicine aims to become a "new infrastructure" for global antibody drugs, leveraging its technology platform to enhance its role in the global pharmaceutical supply chain [5][6] Group 3: Technological Advancements - The integration of AI and big data is transforming drug development, with Hengrui Medicine utilizing AI to optimize antibody efficacy and explore new therapeutic targets [7] - The company has partnered with Insilico Medicine to advance AI-driven antibody discovery, enhancing its capabilities in treating complex diseases [7] - Hengrui Medicine is also focusing on expanding its self-developed pipeline, particularly in the inflammation and immunology sectors, with several candidates nearing clinical trials [8] Group 4: Market Challenges and Opportunities - The Chinese innovative drug industry is thriving but faces issues such as homogenization and intense competition, necessitating diverse business models for sustainable growth [8] - The company emphasizes the importance of recognizing the long and complex nature of the innovative drug industry, advocating for a coexistence of various development models to create a sustainable innovation matrix [8]

Group 1 - The core viewpoint is that the value reassessment of innovative drugs is driven by overseas expansion and clinical breakthroughs, with significant growth in transaction volume and quantity in the first half of 2025 [1] - The total transaction amount related to innovative drugs in China reached $60.8 billion in the first half of 2025, a year-on-year increase of 129%, with 144 transactions, up 67% year-on-year [1] - The recognition of the value of innovative drugs by overseas multinational corporations (MNCs) is rapidly increasing, particularly in areas such as PD-1 bispecific antibodies, where Chinese companies have gained a leading edge [1] Group 2 - The focus is on the three-antibody combination, such as CD3/CD38/BCMA, which shows positive efficacy in hematological and solid tumors, with domestic three-antibody SIM0500 already authorized [1] - GLP-1 class drugs are reshaping the market with global sales revenue exceeding $50 billion, and the transaction volume in the weight loss sector in the first half of 2025 is 1.5 times that of the entire year of 2024 [1] - Breakthroughs in the autoimmune field, such as the international market development of Tai Tasi Pi through MG clinical data advantages, are highlighted [1]